NCT04280224

NK Cells Treatment for COVID-19

Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Henan Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCoV infection. Natural killer (NK) cells are innate lymphocytes that may serve as useful effectors against danger infection. The purpose of this clinical investigation is to evaluate the safety and efficiency of NK Cells in combination with standard therapy for pneumonia patients infected with 2019-nCoV.

Conditions

• Novel Coronavirus Pneumonia

Interventions

Type	Name	Description
BIOLOGICAL	NK Cells	twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)

Timeline

• Start date: 2020-02-15
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2020-02-21
• Last updated: 2024-02-08

Locations

1 site across 1 country: China